Seven Eight Capital LP Grows Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Seven Eight Capital LP lifted its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 1,407.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 169,612 shares of the biotechnology company’s stock after purchasing an additional 158,358 shares during the quarter. Seven Eight Capital LP owned 0.08% of BioCryst Pharmaceuticals worth $1,048,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of BCRX. CWM LLC boosted its stake in BioCryst Pharmaceuticals by 200.0% in the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after buying an additional 3,772 shares in the last quarter. Signaturefd LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 560.5% in the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 5,599 shares during the last quarter. Quarry LP purchased a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $54,000. nVerses Capital LLC bought a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter valued at $63,000. Finally, Natixis raised its position in BioCryst Pharmaceuticals by 400.6% in the 1st quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 9,350 shares during the period. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock opened at $8.11 on Friday. The firm has a market cap of $1.67 billion, a P/E ratio of -7.58 and a beta of 1.88. The business’s 50 day moving average price is $7.79 and its 200-day moving average price is $6.35. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.11. The company had revenue of $109.30 million for the quarter, compared to analysts’ expectations of $98.30 million. During the same period in the previous year, the firm posted ($0.24) earnings per share. The firm’s revenue for the quarter was up 34.9% compared to the same quarter last year. As a group, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.45 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. JMP Securities lifted their price target on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 6th. Barclays increased their price objective on BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 6th. StockNews.com raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $14.17.

Insider Activity at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, Director Amy E. Mckee sold 8,600 shares of the firm’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $6.32, for a total value of $54,352.00. Following the completion of the sale, the director now directly owns 27,831 shares in the company, valued at $175,891.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.80% of the stock is owned by corporate insiders.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.